Application and therapeutic mechanism of Durvalumab and Tremelimumab monotherapy or combination in tumor treatment

Abstract

Monoclonal antibodies (mAbs) have transformed from scientific tools to potent human therapeutics. Monoclonal antibody therapy has become an important treatment modality for cancer due to its strong specificity and remarkable curative effect. Among them, Durvalumab is a PD-L1 inhibitor. In anticipation of achieving a better clinical response with different drugs in combination therapy, the researchers decided to combine Durvalumab with the anti-CTLA-4 drug Tremelimumab. In addition, this type of immunotherapy is actively used as a novel treatment option for various cancers. This paper reviews the mechanism of action of Durvalumab and Tremelimumab in prospective randomized trials as a single or combination therapy for cancer and their applicability to different tumor types.